MedTrace Logo

WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults

NCT07216651 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2026-03-19

No results posted yet for this study

Summary

This research study is studying WeDosify, an interactive web-based Clinical Decision Support tool that assists healthcare professionals in managing adults with excess weight or obesity using a Glucagon-like peptide-1 (GLP-1) drug treatment such as semaglutide.

Conditions

  • Obesity & Overweight

Sponsors & Collaborators

  • Closed Loop Medicine

    lead INDUSTRY

Principal Investigators

  • Susan Neese, MD · Amarillo Premier Research

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-23
Primary Completion
2026-02-27
Completion
2026-03-18

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07216651 on ClinicalTrials.gov